Strongbridge Biopharma plc Operating Income

The latest operating income for SBBP is $-43M as of June 2021. That compares with $-54M in the prior-year period — up 19.4% year over year. Investors often review this figure alongside Strongbridge Biopharma plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, SBBP's operating income moved from $-54M to $-43M — a 19.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Strongbridge Biopharma plc's operating scale or balance-sheet position.

A operating income figure of $-43M for SBBP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SBBP's operating income ($-43M), review year-over-year change from $-54M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Strongbridge Biopharma plc's operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.